I
26.14
-0.13 (-0.49%)
| Penutupan Terdahulu | 26.27 |
| Buka | 25.72 |
| Jumlah Dagangan | 1,326,810 |
| Purata Dagangan (3B) | 1,786,780 |
| Modal Pasaran | 5,266,596,352 |
| Harga / Buku (P/B) | 10.18 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Feb 2026 |
| EPS Cair (TTM) | -2.73 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.01% |
| Nisbah Semasa (MRQ) | 11.16 |
| Aliran Tunai Operasi (OCF TTM) | -375.87 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -227.82 M |
| Pulangan Atas Aset (ROA TTM) | -37.97% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.46% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Immunovant, Inc. | Menaik | Menurun |
AISkor Stockmoo
-0.5
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | -0.50 |
|
Immunovant Inc is a clinical-stage biopharmaceutical company. It is focused on enabling normal lives for patients with autoimmune diseases. The company's product includes batoclimab and IMVT-1402 targets the neonatal Fc receptor (FcRn). |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 58.17% |
| % Dimiliki oleh Institusi | 55.78% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 50.00 (Wolfe Research, 91.28%) | Beli |
| Median | 28.00 (7.12%) | |
| Rendah | 22.00 (Truist Securities, -15.84%) | Pegang |
| Purata | 33.33 (27.51%) | |
| Jumlah | 1 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 26.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 08 Jan 2026 | 22.00 (-15.84%) | Pegang | 26.31 |
| Wolfe Research | 06 Jan 2026 | 50.00 (91.28%) | Beli | 25.90 |
| Goldman Sachs | 15 Dec 2025 | 28.00 (7.12%) | Pegang | 26.00 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 11 Dec 2025 | Pengumuman | Immunovant Announces Pricing of $550 Million Common Stock Financing |
| 10 Nov 2025 | Pengumuman | Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025 |
| 27 Oct 2025 | Pengumuman | Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |